-
Febuxostat downgraded to second-line medication?
Time of Update: 2022-01-09
(Level of Evidence: Medium) For patients who have failed to reach the SU target after XOI treatment, uric acid excretion drug treatment and other interventions, but have infrequent gout attacks (<2 times/year) and no tophi, it is strongly recommended to continue the current ULT Plan instead of converting to Precish .
-
These rheumatism are the most "sad"!
Time of Update: 2022-01-09
In fact, the primary prevention guidelines of the European Society of Cardiology (ESC) and the American Heart Association (AHA) have pointed out that psoriasis, rheumatoid arthritis (RA), human immunodeficiency virus (HIV) and systemic lupus erythematosus (SLE) ) CID is a risk factor for atherosclerotic cardiovascular disease (ASCVD) .
-
Express US FDA approved the 50th new drug this year!
Time of Update: 2022-01-09
▲Adbry (TRAL in the picture) binds to IL-13 to block its binding to IL-13Rα1 and IL-13Rα2 (picture source: reference [2]) Adbry's approval this time is based on 3 key points 3 According to the positive safety and efficacy results of the phase trial, a total of about 2,000 adult patients with moderate to severe atopic dermatitis were enrolled .
-
Professor Chunfu Zheng published a review of the latest research progress on the role of CDK in antiviral innate immunity in JMV (there are eggs at the end of the article)
Time of Update: 2022-01-09
Recently, Professor Chunfu Zheng published a review in the Journal of Medical Virology (JMV): The emerging roles of the CDK/cyclincomplexes in antiviral innate immunity .
-
1 case, 2 tables, the clinical manifestations of sarcoidosis have been clarified!
Time of Update: 2022-01-09
This is because the clinical manifestations of patients with sarcoidosis are very heterogeneous, ranging from no obvious clinical symptoms to progressive disease, which can lead to decreased lung function.
-
There are 5 types of APS-related cardiovascular diseases!
Time of Update: 2022-01-09
APS and heart valve disease Professor Zhou Zhou mentioned that in clinical work, while solving the patient's valve disease, we must pay attention to the diagnosis of etiology, and briefly introduced a case (see Figure 4): Clinical problem: young patients , Repeated arterial and venous thrombosis, poor prognosis, high incidence of malignant events, need to find the cause, and adjust the treatment plan according to the cause .
-
Hong Kong University of Science and Technology Research: Human T cell immune response can effectively respond to Omi Keron
Time of Update: 2022-01-09
The research team expects that the T cell immune barrier produced after vaccination and booster will continue to protect humans and reduce the chance of being infected by Omi Keron or other mutant viruses .
-
22 recommendations, APLAR Gout Guide is here!
Time of Update: 2022-01-09
In this regard, the "2021 Asia Pacific Rheumatism Alliance (APLAR) Gout Treatment Clinical Practice Guidelines (CPG)" has been published in the "International Journal of Rheumatology" (Int J Rheum Dis), let us learn together .
-
Professor Zeng Xiaofeng: Can the exploration of targeted therapy improve the "less drug" situation in SLE?
Time of Update: 2022-01-09
Figure 3: "2020 China Systemic Lupus Erythematosus Diagnosis and Treatment Guidelines" According to our current understanding of the disease mechanism, B cells are an important factor in the progression of SLE disease, and therapeutic strategies targeting B cells have attracted much attention .
-
Nat Immunol Multi-unit cooperation of Army Military Medical University, Ye Lilin/Yin Zhinan/Xu Jianqing reveals a new mechanism of virus-specific CD4+ T cell immune memory maintenance
Time of Update: 2022-01-09
On December 23, 2021, Ye Lilin of Army Military Medical University, Yin Zhinan of Jinan University and Xu Jianqing of Fudan University jointly published a study titled "The kinase complex mTORC2 promotes the longevity of virus-specific memory CD4+ T cells by preventing ferroptosis" in Nature Immunology.
-
Gout patients don’t take medicine well, and it will be so severe after 5 years?
Time of Update: 2022-01-09
Allopurinol, febuxostat, or benzbromarone are recommended as the first-line medication for lowering uric acid in patients with gout .
Allopurinol is recommended as the first-line medication for lowering uric acid in patients with hyperuricemia and gout.
-
Although this kind of overlap syndrome is rare, don't get lucky!
Time of Update: 2022-01-09
Figure 1: Recommendations for the treatment of SLE issued by the GLADEL-PANLAR guidelines in 2018 ABT: Abatacept, SOC: conventional treatments, such as hormones (GCs), antimalarials (AMs), IS: a retrospective study of immunosuppressants Six patients with Rhupus syndrome (all with refractory arthritis and non-life-threatening organ damage) were enrolled, and their condition was not effectively relieved under the treatment of traditional DMARDs such as MTX, tacrolimus and cyclosporine .
-
Febuxostat downgraded to second-line medication?
Time of Update: 2022-01-09
(Level of Evidence: Medium) For patients who have failed to reach the SU target after XOI treatment, uric acid excretion drug treatment and other interventions, but have infrequent gout attacks (<2 times/year) and no tophi, it is strongly recommended to continue the current ULT Plan instead of converting to Precish .
-
JEADV: Study on circulating phospholipase A2, IVD, DNA in patients with psoriasis
Time of Update: 2022-01-08
The number of circulating PLA2G4D DNA copies in patients with psoriasis was significantly higher than that in healthy controls.
-
What exactly do X-ray examinations look for in patients with ankylosing spondylitis?
Time of Update: 2022-01-08
X-ray appearance of rigidityX-ray appearance of rigidity X-ray appearance of rigidity0 1 Sacroiliac joint0 1 Sacroiliac joint 1Early manifestations are 2/3 spot-like or plaque-like bone decalcification under the sacroiliac joint, blurred edges, mild subchondral sclerosis, occasional beaded shadows, and unplanned widening of the joint space .
-
Front Oncol: Clinicopathological characteristics, treatment strategies and prognostic factors of Merkel cell carcinoma (MCC)
Time of Update: 2022-01-08
Many patients use immunomodulatory drugs (59 cases, 41%),Extensive resection (WE) is the most common treatment for the primary lesion (101 cases, 71%) .
In patients with stage I-III who received extensive resection of the primary tumor and received SNB treatment, the recurrence-free survival was not related to SNB positive (HR=1.
-
Cell Metab impaired thermogenesis in cold environments and gender-dependent systemic inflammation are all related to UCP1
Time of Update: 2022-01-08
The above interventions partially activate a protein uniquely expressed in BAT and beige fat, the thermogenic effector uncoupling protein 1 (uncoupling protein 1, UCP1) to initiate thermogenesis of adipose tissue, and UCP1 remains inactive under basal conditions State, but when activated, it will cause protons to leak through the inner mitochondrial membrane, thereby significantly increasing the catabolism of reducing substrates from glucose and fat [1, 2] .
-
JAMA Dermatol: It's time for pustular psoriasis to get more attention
Time of Update: 2022-01-08
Hundreds of millions of dollars have been invested for the development of psoriasis vulgaris efficient drugs, but still not the US Food and Drug Administration Bureau ( the FDA pustular psoriasis for localized or) approval (GPP) of Treatment methods .
-
Br J Dermatol: Are antipsoriatic drugs better for women than men?
Time of Update: 2022-01-08
Psoriasis is a chronic inflammatory skin disease that affects about 2.
They followed up for one year after starting treatment, and women showed better improvement than men on the Psoriasis Area and Severity Index (PASI) and Dermatological Quality of Life Index (DLQI).
-
ARD: lifetime risk of interstitial lung disease associated with rheumatoid arthritis in MUC5B mutation carriers
Time of Update: 2022-01-08
Based on the strongest known risk factor for pulmonary fibrosis (a MUC5B promoter mutation), the lifetime risk of developing rheumatoid arthritis-related interstitial lung disease (RA-ILD) is assessed .
